ISIN:FR0011191287

Pharnext strengthens its ties with Néovacs to secure the next steps in its development

Retrieved on: 
Dimanche, janvier 22, 2023
Communication, Regulatory News Service, CET, Medtech, Research, CFO, Biotechnology, Patient, Degenerative disease, Confidentiality, Investment, FDA, Therapy, Sciences Po, EMA, Verney-Carron, Marketing, Neurodegeneration, Hugo, Security (finance), Pharmaceutical industry, Health insurance, Management, Euronext

Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.

Key Points: 
  • Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.
  • This new financing agreement is a partial or total complement to the OCEANE-BSA financing granted by Global Tech Opportunities 13 ("GTO 13").
  • However, Néovacs, through the trust managing its financing contract with Pharnext, has agreed to subscribe to the €1 million tranche scheduled for late December.
  • It was unbelievable that the Company would find itself in difficulty and that is why Néovacs decided to support it.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Dimanche, janvier 22, 2023
General counsel, Warner Chilcott, CMC, Regulatory News Service, Master of Pharmacy, CET, United States Department of the Navy, Pharmacovigilance, MD, Johnson & Johnson, Pfizer, Good laboratory practice, Good manufacturing practice, Capsule, Eastern University, Sri Lanka, NDA, BA, Good clinical laboratory practice, Patient, Organization, Regulatory affairs, SLT, Therapy, Charcot–Marie–Tooth disease, Cellectis, Eastern University, Master of Science, Quality assurance, Tablet, Scott, Bachelor of Science, Gan, Doctor of Philosophy, Neurodegeneration, Hugo, Management, Pharmaceutical industry, Medical device, Sanofi, Quality

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company

Retrieved on: 
Lundi, novembre 28, 2022
Committee, Patient, ISIN, Neurodegeneration, CET, Regulatory News Service, Risk, Therapy, Charcot–Marie–Tooth disease, Management, Security (finance), Pharmaceutical industry

The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company

Key Points: 
  • The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
    PARIS, France, November 28th, 2022, 8:30 am CET Pharnext SA (FR001400BV89 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company.
  • At the Board of Directors meeting held on November 27th, 2022, Dr. David Horn SOLOMON presented his resignation, with immediate effect, from his duties as Chief Executive Officer and Director of Pharnext SA.
  • The Board expressed its thanks to Dr. David Horn SOLOMON for his contributions.

Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions

Retrieved on: 
Dimanche, novembre 27, 2022
Risk, Therapy, Parity, ISIN, Charcot–Marie–Tooth disease, Neurodegeneration, Treasury, Exercise, Security (finance)

These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.

Key Points: 
  • These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.
  • The Company also carried out two capital reductions motivated by losses.
  • As a result of this capital reduction, the share capital is reduced from 3,932,043 euros to 39,320.43 euros and is divided into an unchanged number of shares, i.e.
  • Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments.

Hugo Brugière Joins Pharnext Board of Directors

Retrieved on: 
Vendredi, novembre 11, 2022
CET, Sciences Po, Risk, ISIN, Board, Regulatory News Service, Board of directors, Charcot–Marie–Tooth disease, Hugo, CEO, Therapy, Neurodegeneration, Trial of the century, Security (finance), Pharmaceutical industry, Management

PARIS, France, on November 8th, 2022 at 8:30am (CET) Pharnext SA (FR0011191287 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its Board of Directors has appointed Hugo Brugire, Chairman and CEO of Novacs, as a new Director.

Key Points: 
  • PARIS, France, on November 8th, 2022 at 8:30am (CET) Pharnext SA (FR0011191287 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its Board of Directors has appointed Hugo Brugire, Chairman and CEO of Novacs, as a new Director.
  • This cooptation will be submitted to the approval of the next shareholders meeting of Pharnext.
  • This follows the financing agreement executed between Pharnext and Novacs for an amount of 20.7 million net as announced on October 3rd, 2022.
  • Joshua Schafer, Chairman of Pharnexts Board of Directors, commented: I am delighted to welcome Hugo Brugire as a new member of our Board of Directors as we advance our pivotal Phase III clinical study of PXT3003, the PREMIER trial, which is due to bring top line data in Q4 2023.